Sanofi scraps oral SERD strategy after 2nd failure in breast cancer

Sanofi is stopping development of its oral selective estrogen receptor degrader (SERD) amcenestrant. A failed phase 3 interim analysis dealt the death blow to the program, which Sanofi once saw as the future “endocrine backbone therapy” in breast cancer.